LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Accueil・Liste d'Actions・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Fermé

SecteurSoins de santé

15.44 2.86

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

15.02

Max

15.49

Chiffres clés
By Trading Economics
Revenu	-130B -25B
Ventes	-99B 1.1T
P/E Moyenne du Secteur	39.974 49.888
BPA	0.21
Rendement du dividende	4.35
Marge bénéficiaire	-2.222
Employés	47,455
EBITDA	-242B 214B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+39.72% upside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	4.35% 2.38%

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-3.7B 48B
Ouverture précédente	12.58
Clôture précédente	15.44

Sentiment de l'Actualité

By Acuity

100%

325 / 344 Classement par Healthcare

Takeda Pharmaceutical Co Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 mai 2026, 08:59 UTC

Résultats

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

29 janv. 2026, 07:11 UTC

Résultats

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19 déc. 2025, 03:32 UTC

Principaux Mouvements du Marché

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30 oct. 2025, 09:39 UTC

Résultats

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30 oct. 2025, 07:32 UTC

Résultats

Takeda Posts Quarterly Net Loss, Cuts Guidance

13 mai 2026, 06:57 UTC

Résultats

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

13 mai 2026, 06:54 UTC

Résultats

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

13 mai 2026, 06:44 UTC

Résultats

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

13 mai 2026, 06:38 UTC

Résultats

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

13 mai 2026, 06:31 UTC

Résultats

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

13 mai 2026, 06:31 UTC

Résultats

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 mai 2026, 06:31 UTC

Résultats

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13 mai 2026, 06:31 UTC

Résultats

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

13 mai 2026, 06:31 UTC

Résultats

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 mai 2026, 06:31 UTC

Résultats

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

29 janv. 2026, 06:53 UTC

Résultats

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29 janv. 2026, 06:36 UTC

Résultats

Takeda Raises FY Revenue, Net-Profit Views

29 janv. 2026, 06:34 UTC

Résultats

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29 janv. 2026, 06:33 UTC

Résultats

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29 janv. 2026, 06:32 UTC

Résultats

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29 janv. 2026, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 janv. 2026, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29 janv. 2026, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29 janv. 2026, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 janv. 2026, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29 janv. 2026, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30 oct. 2025, 07:10 UTC

Résultats

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30 oct. 2025, 06:50 UTC

Résultats

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30 oct. 2025, 06:49 UTC

Résultats

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30 oct. 2025, 06:48 UTC

Résultats

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Comparaison

Variation de prix

Takeda Pharmaceutical Co Ltd ADR prévision

Objectif de Prix

By TipRanks

39.72% hausse

Prévisions sur 12 Mois

Moyen 21 USD 39.72%

Haut 21 USD

Bas 21 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.